# Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

> **NCT00788125** · PHASE1,PHASE2 · TERMINATED · sponsor: **City of Hope Medical Center** · enrollment: 7 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors
- Childhood Germ Cell Tumor
- Extragonadal Germ Cell Tumor
- Kidney Cancer
- Liver Cancer
- Lymphoma
- Neuroblastoma
- Ovarian Cancer
- Sarcoma
- Testicular Germ Cell Tumor
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** carboplatin
- **DRUG:** dasatinib
- **DRUG:** etoposide phosphate
- **DRUG:** ifosfamide
- **GENETIC:** microarray analysis
- **GENETIC:** western blotting
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** therapeutic conventional surgery
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00788125
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09-03
- **Primary completion:** 2010-04-30
- **Final completion:** 2022-07-30
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Terminated early due a shift in resources after lackluster performance of the drug.
- **Last updated:** 2023-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00788125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00788125, "Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00788125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*